Pay in 4 interest-free payments of $6.89 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Studies estimate that upper gastrointestinal bleeding affects approximately 50 to 100 people per 100,000 annually, with melena being one of the most recognisable symptoms
Clinical trials have consistently demonstrated that semaglutide treatment is associated with reductions in total cholesterol, low-density lipoprotein cholesterol (LDL-C), and triglycerides, along with small and sometimes variable changes in high-density lipoprotein cholesterol (HDL-C)
A thorough clinical evaluation is warranted to identify alternative explanations and ensure appropriate management
Current guidance states that treatment is indicated for adults with a BMI of 30 or above, or a BMI of 27 or above where there is at least one weight-related health condition, including in some higher-risk ethnic groups where lower BMI thresholds may still be clinically relevant
US$ 26.98
US$ 22.99
US$ 27.08
US$ 22.64
US$ 29.00
